New eczema treatment shows promise everyday health gas utility austin

#

It is itchy and irritatingly hard to treat. Topical dermatitis, or eczema, is a chronic skin disease, characterized by red and itchy skin, which may lead to rashes and infections. The only eczema treatments or therapies available are topical steroids, nonsteroidal topical ointment, topical antibiotics, injectables that block allergic pathways, and antihistamines for itching. But these remedies can be slow-acting, expensive, and in some cases, ineffective: Some bacteria are showing resistance to antibiotics and other antibacterial therapies.

Two current studies are looking at the efficacy of using healthy bacteria to get rid of the bad bacteria causing the disease response, restoring the natural microbial balance of healthy skin. When researchers look at the skin of someone with eczema, they have found:

Twice a week for six weeks, 10 adults and 5 children applied a spray containing Roseomonas mucosa, a healthful, naturally occurring bacterium. Six of the 10 adults had a 75 percent improvement in the itching, the rash, and the amount of topical steroids they felt they needed to keep their disease under control. Four out of the five children had the same 75 percent improvement. No one reported an adverse effect or complication.

Of those who didn’t improve, most had strong family histories of the skin disease. “Most people outgrow eczema by the time they are 6 or 7. If you have multiple generations who have had the disease long into adulthood, it’s probably a different breed of the disease, so to speak. It may be that they don’t have a bacteria problem; it’s more about a genetic issue that has to be addressed a different way. The take-home: Ten out of 15 people had dramatic improvement with no problems,” said NIAID’s Ian Myles, MD, the principal investigator.

The research team will now test the safety and efficacy of the spray on children as young as 3, and then start a double-blind trial in which participants get either a placebo or the real thing. “We’re probably two or three years removed from this [treatment] becoming publicly available,” says Dr. Myles. A Second Eczema Treatment Study Is Also on the Bacterial Trail

Researchers at National Jewish Health in Denver are also exploring this unique treatment option in collaboration with the University of California in San Diego. The team has created a cream using a different strain of “good” bacteria, Staphylococcus hominis, which produces proteins that act like antibiotics by killing Staph aureus. Last year, they reported positive results on an initial trial. NJH is currently recruiting for participants for a placebo trial.

“We believe the microbiome is very important in controlling healing of the skin as well as maturation to build better barriers to the environment. Good bacteria that kills bad bacteria also works on the underlying skin to heal it to make it a healthy skin,” says Donald Leung, MD, the head of the division of pediatric allergy and immunology at National Jewish Health. Antibiotic Resistance Makes Eczema Harder to Treat

“The reason this is important is because we are running out of antibiotics to kill S taph aureus,” he adds. “It is outsmarting us by mutating and producing enzymes that can prevent the antibiotics from working. One of the pluses of this therapy is that instead of giving antibiotics, we can give good bacteria. We may perhaps create a cocktail of them, because each bacterial group brings a different set of proteins and antibiotics that contribute to the health of the skin. Think of it as probiotics of the skin to recolonize the host.”

Currently, there is no cure for eczema, only therapies to reduce incidence and intensity. But the future may bring some relief to people living with eczema: “We don’t know if it’s going to be a cure or simply a better treatment, because we are really not far enough along. That’s true of the other study as well. It’s too early to know. It’s a new approach and it may get us away from overuse of antibiotics, which is really causing trouble,” says Dr. Leung.